SHANGHAI, China — Hope Medicine Inc. , a clinical-stage innovative biopharmaceutical company, announced recently that the company has completed a Phase Ib study, “An Open-Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period”. This study is...
treatment News
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of a retrospective analysis of the pivotal Phase 2/3 N-MOmentum clinical trial, indicating UPLIZNA may provide durable efficacy and a favorable safety profile for African Americans with NMOSD. These data were presented during the 15th World Congress on Controversies in Neurology (CONy Virtual), Sept....
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 trial to evaluate its development-stage medicine HZN-7734 (formerly VIB7734), a first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7), to treat people with moderate to severely active systemic lupus erythematosus (SLE)....
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved a prior approval supplement (PAS) to the previously approved Biologics Licensing Application (BLA) giving Horizon authorization to manufacture more TEPEZZA drug product resulting in an increased number of vials with each...
NEW YORK – Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it submitted an Orphan Drug Designation Request to the US Food and Drug Administration (FDA) for HT-KIT for the treatment of mastocytosis. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frameshifting, resulting in the...
Mumbai, India – In November last year, Pratiksha Mane, 48, underwent surgery for Ewing’s Sarcoma, a rare form of breast cancer. She was diagnosed with cancer in her right breast, which was conserved post sugery by doctors at Mumbai’s Jaslok Hospital & Research Centre. As per the American Academy of...
San Francisco, CA – For Paul Bresge, getting into biotech wasn’t fulfilling a career goal. It was fulfilling a promise. One of his daughters, Tamar, was diagnosed with retinitis pigmentosa in 2010 at the age of 15, when the family was living in Toronto. “We were basically told—in the whole...
Sydney, Australia – UNSWmedical researcher Dr David Jacques and his team have discovered how the human immunodeficiency virus (HIV) breaches the cell nucleus to establish infection, a finding that has implications beyond HIV biology. To infect cells, HIV must enter the target cell and make its way to the nucleus...
LA JOLLA, CA —Pancreatic cancer is one of the deadliest cancers—only about one in eight patients survives five years after diagnosis. Those dismal statistics are in part due to the thick, nearly impenetrable wall of fibrosis, or scar tissue, that surrounds most pancreatic tumors and makes it hard for drugs...
SHANGHAI and CLINTON, N.J. — HuidaGene Therapeutics today announced the U.S. FDA granted Rare Pediatric Drug Designation (RPDD) to HG302, a novel CRISPR-Cas12 DNA-editing therapy, to treat Duchenne muscular dystrophy (DMD), affecting 1 in ~5,000 newborn boys. Unlike the in-vivo use of Cas9 system with limited genome-editing efficiency, high occurrence...